Blood test may predict dangerous MS rebound after stopping popular drug
NCT ID NCT05828901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small, early-terminated study explored whether measuring certain receptors on immune cells could predict disease activity and rebound risk in multiple sclerosis patients taking or stopping ozanimod. Researchers analyzed blood samples from 23 adults with relapsing-remitting MS before and after starting or stopping the drug. The goal was to find a biomarker that could guide safer treatment decisions, but the study's limited size and early stop mean the findings are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ozanimod
What this could lead to
If successful, this could help doctors identify which MS patients are at risk of severe relapse after stopping ozanimod, allowing safer treatment switches.
What could go wrong
The study was terminated early with only 23 participants, so results are limited. It was exploratory, not designed to prove a treatment works, and the biomarker approach may not be reliable in practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurology department
Bern, 3010, Switzerland